Anti-progestin therapy targets hallmarks of breast cancer risk

The BC-APPS1 study

The BC-APPS1 was a single-arm, single-centre phase II study registered under the name ‘a pilot prevention study of the effects of the anti-progestin ulipristal acetate (UA) on surrogate markers of breast cancer risk’…